{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:44:46Z","timestamp":1790174686602,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05113-2","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:09:33Z","timestamp":1772161773000},"page":"11975-11991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study"],"prefix":"10.1007","volume":"399","author":[{"given":"Meixuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mixue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"3","key":"5113_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4239\/wjd.v15.i3.331","volume":"15","author":"SF Alqifari","year":"2024","unstructured":"Alqifari SF, Alkomi O, Esmail A, Alkhawami K, Yousri S, Muqresh MA, Alharbi N, Khojah AA, Aljabri A, Allahham A, Prabahar K, Alshareef H, Aldhaeefi M, Alrasheed T, Alrabiah A, AlBishi LA (2024) Practical guide: glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus. World J Diabetes 15(3):331\u2013347. https:\/\/doi.org\/10.4239\/wjd.v15.i3.331","journal-title":"World J Diabetes"},{"issue":"2","key":"5113_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3892\/ijmm.2014.1787","volume":"34","author":"E Aoyama","year":"2014","unstructured":"Aoyama E, Watari I, Podyma-Inoue KA, Yanagishita M, Ono T (2014) Expression of glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells. Int J Mol Med 34(2):475\u201382. https:\/\/doi.org\/10.3892\/ijmm.2014.1787","journal-title":"Int J Mol Med"},{"key":"5113_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825417","volume":"13","author":"S Chai","year":"2022","unstructured":"Chai S, Liu F, Yang Z, Yu S, Liu Z, Yang Q, Sun F (2022) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. Front Pharmacol 13:825417. https:\/\/doi.org\/10.3389\/fphar.2022.825417","journal-title":"Front Pharmacol"},{"issue":"1","key":"5113_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8145388","volume":"2024","author":"S Chai","year":"2024","unstructured":"Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F (2024) Comparison of GLP\u20101 receptor agonists, SGLT\u20102 inhibitors, and DPP\u20104 inhibitors as an add\u2010on drug to insulin combined with oral hypoglycemic drugs: umbrella review. J Diabetes Res 2024(1):8145388. https:\/\/doi.org\/10.1155\/2024\/8145388","journal-title":"J Diabetes Res"},{"issue":"1","key":"5113_CR5","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2474","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen C, Zhou R, Fu F, Xiao J (2023) Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatry 66(1):e99. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2474","journal-title":"Eur Psychiatry"},{"key":"5113_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.diabres.2016.10.021","volume":"122","author":"A Courties","year":"2016","unstructured":"Courties A, Sellam J (2016) Osteoarthritis and type 2 diabetes mellitus: what are the links? Diabetes Res Clin Pract 122:198\u2013206. https:\/\/doi.org\/10.1016\/j.diabres.2016.10.021","journal-title":"Diabetes Res Clin Pract"},{"key":"5113_CR7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"5113_CR8","doi-asserted-by":"publisher","unstructured":"Deacon CF, Mannucci E, Ahr\u00e9n B (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 14(8). https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01603.x","DOI":"10.1111\/j.1463-1326.2012.01603.x"},{"issue":"5","key":"5113_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1302\/2046-3758.105.BJR-2021-0119","volume":"10","author":"A Eitner","year":"2021","unstructured":"Eitner A, Wildemann B (2021) Diabetes \u2013 osteoarthritis and joint pain. Bone Jt Res 10(5):307\u2013309. https:\/\/doi.org\/10.1302\/2046-3758.105.BJR-2021-0119","journal-title":"Bone Jt Res"},{"issue":"6","key":"5113_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5113_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2020.00178","journal-title":"Front Endocrinol"},{"issue":"1","key":"5113_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00447-w","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Jia Y, Sun S, Meng L (2020) Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol 21(1):68. https:\/\/doi.org\/10.1186\/s40360-020-00447-w","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"5113_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14740338.2024.2376686","volume":"24","author":"Y Huo","year":"2025","unstructured":"Huo Y, Ma M, Liao X (2025) Data mining study on adverse events of tirzepatide based on FAERS database. Expert Opin Drug Saf 24(6):675\u2013683. https:\/\/doi.org\/10.1080\/14740338.2024.2376686","journal-title":"Expert Opin Drug Saf"},{"key":"5113_CR14","doi-asserted-by":"publisher","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","DOI":"10.1056\/NEJMoa2107519"},{"key":"5113_CR15","doi-asserted-by":"publisher","unstructured":"Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 30(10):1923\u20131940. https:\/\/doi.org\/10.1007\/s00198-019-04968-x","DOI":"10.1007\/s00198-019-04968-x"},{"issue":"7","key":"5113_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073050","volume":"26","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Theofilis P, Pamporis K, Sagris M, Vlachakis PK, Koufakis T, Antoniadis AP, Fragakis N (2025) GLP-1 receptor agonists and myocardial perfusion: bridging mechanisms to clinical outcomes. Int J Mol Sci 26(7):3050. https:\/\/doi.org\/10.3390\/ijms26073050","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5113_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM (2022) A standardized dataset of a spontaneous adverse event reporting system. Healthcare 10(3):420. https:\/\/doi.org\/10.3390\/healthcare10030420","journal-title":"Healthcare"},{"issue":"1","key":"5113_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita S, Hosomi K, Yokoyama S, Takada M (2020) Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther 45(1):65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"5113_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3164\/jcbn.17-64","volume":"63","author":"N Kitagawa","year":"2018","unstructured":"Kitagawa N, Hamaguchi M, Majima S, Fukuda T, Kimura T, Hashimoto Y, Tanaka M, Yamazaki M, Nakamura N, Fukui M (2018) Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells. J Clin Biochem Nutr 63(2):106\u2013112. https:\/\/doi.org\/10.3164\/jcbn.17-64","journal-title":"J Clin Biochem Nutr"},{"key":"5113_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol 13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol"},{"key":"5113_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102849","volume":"66","author":"C Luna-Marco","year":"2023","unstructured":"Luna-Marco C, de Mara\u00f1on AM, Hermo-Argibay A, Rodriguez-Hernandez Y, Hermenejildo J, Fernandez-Reyes M, Apostolova N, Vila J, Sola E, Morillas C, Rovira-Llopis S, Rocha M, Victor VM (2023) Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol 66:102849. https:\/\/doi.org\/10.1016\/j.redox.2023.102849","journal-title":"Redox Biol"},{"key":"5113_CR22","doi-asserted-by":"publisher","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","DOI":"10.1056\/NEJMoa1603827"},{"issue":"5","key":"5113_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","volume":"39","author":"A Mascolo","year":"2016","unstructured":"Mascolo A, Rafaniello C, Sportiello L, Sessa M, Cimmaruta D, Rossi F (2016) Capuano A (2016) Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis\/arthralgia: a review of clinical cases. Drug Saf 39(5):401\u2013407. https:\/\/doi.org\/10.1007\/s40264-016-0399-8","journal-title":"Drug Saf"},{"issue":"9","key":"5113_CR24","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","volume":"21","author":"F Mazhar","year":"2021","unstructured":"Mazhar F, Battini V, Gringeri M, Pozzi M, Mosini G, Marran AMN, Akram S, van Manen RP, Radice S, Clementi E, Carnovale C (2021) The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther 21(9):1281\u20131290. https:\/\/doi.org\/10.1080\/14712598.2021.1948529","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"5113_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2016.153","volume":"13","author":"N Napoli","year":"2017","unstructured":"Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13(4):208\u2013219. https:\/\/doi.org\/10.1038\/nrendo.2016.153","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"5113_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.5603\/EP.a2022.0029","volume":"73","author":"M Nowak","year":"2022","unstructured":"Nowak M, Nowak W, Grzeszczak W (2022) Tirzepatide - a dual GIP\/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynol Pol 73(4):745\u2013755. https:\/\/doi.org\/10.5603\/EP.a2022.0029","journal-title":"Endokrynol Pol"},{"issue":"1","key":"5113_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13677","volume":"16","author":"VJ Old","year":"2025","unstructured":"Old VJ, Davies MJ, Papamargaritis D, Choudhary P, Watson EL (2025) The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review. J Cachexia Sarcopenia Muscle 16(1):e13677. https:\/\/doi.org\/10.1002\/jcsm.13677","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"5113_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-022-00410-2","volume":"9","author":"M Razavi","year":"2022","unstructured":"Razavi M, Wei Y-Y, Rao X-Q, Zhong J-X (2022) DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res 9(1):45. https:\/\/doi.org\/10.1186\/s40779-022-00410-2","journal-title":"Mil Med Res"},{"issue":"9","key":"5113_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.4239\/wjd.v12.i9.1426","volume":"12","author":"A Roy","year":"2021","unstructured":"Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D (2021) Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: current evidence. World J Diabetes 12(9):1426\u20131441. https:\/\/doi.org\/10.4239\/wjd.v12.i9.1426","journal-title":"World J Diabetes"},{"key":"5113_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146353","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, Christe ME, Collins KAL, Pirro V, Droz BA, Holland AK, Friedrich JL, Wojnicki S, Konkol DL, Cosgrove R, Furber EPSC, Ruan X, O\u2019Farrell LS, Long AM, Dogra M, Willency JA, Lin Y, Ding L, Cheng CC, Cabrera O, Briere DA, Alsina-Fernandez J, Gimeno RE, Moyers JS, Coskun T, Coghlan MP, Sloop KW, Roell WC (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI146353","journal-title":"J Clin Invest"},{"key":"5113_CR31","doi-asserted-by":"publisher","unstructured":"Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J (2015) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials. Endocrine 48(1):107\u2013115. https:\/\/doi.org\/10.1007\/s12020-014-0361-4","DOI":"10.1007\/s12020-014-0361-4"},{"issue":"6","key":"5113_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25(6):381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001","journal-title":"Drug Saf"},{"issue":"15","key":"5113_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158214","volume":"25","author":"Z Szekeres","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E (2024) Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review. Int J Mol Sci 25(15):8214. https:\/\/doi.org\/10.3390\/ijms25158214","journal-title":"Int J Mol Sci"},{"key":"5113_CR34","doi-asserted-by":"publisher","unstructured":"Tran S, Retnakaran R, Zinman B, Kramer CK (2018) Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 20(Suppl 1):68-76. https:\/\/doi.org\/10.1111\/dom.13137","DOI":"10.1111\/dom.13137"},{"issue":"3","key":"5113_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.33314\/jnhrc.v19i3.3433","volume":"19","author":"B Vaidya","year":"2021","unstructured":"Vaidya B, Adhikari B, Bhochhibhoya M, Nakarmi S (2021) Late onset dipeptidyl peptidase-4 inhibitor associated seronegative rheumatoid arthritis. J Nepal Health Res Counc 19(3):644\u2013646. https:\/\/doi.org\/10.33314\/jnhrc.v19i3.3433","journal-title":"J Nepal Health Res Counc"},{"issue":"3","key":"5113_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030393","volume":"60","author":"A Wikarek","year":"2024","unstructured":"Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawro\u0144ska A, Suchodolska M, Holecki M (2024) Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Medicina 60(3):393. https:\/\/doi.org\/10.3390\/medicina60030393","journal-title":"Medicina"},{"issue":"5","key":"5113_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jdiacomp.2016.02.016","volume":"30","author":"MF Williams","year":"2016","unstructured":"Williams MF, London DA, Husni EM, Navaneethan S, Kashyap SR (2016) Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis. J Diabetes Complications 30(5):944\u2013950. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.02.016","journal-title":"J Diabetes Complications"},{"issue":"560","key":"5113_CR38","first-page":"917","volume":"13","author":"K Zamfirov","year":"2017","unstructured":"Zamfirov K, Philippe J (2017) Musculoskeletal complications in diabetes mellitus. Rev Med Suisse 13(560):917\u2013921","journal-title":"Rev Med Suisse"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05113-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:19:04Z","timestamp":1781511544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05113-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5113"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05113-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the patients\/participants or patients\/participants\u2019 legal guardian\/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}